Modulation of Protein-Protein Interactions as a Therapeutic Strategy for The Treatment of Neurodegenerative Tauopathies

Current Topics in Medicinal Chemistry

Volumn 11, Issue 3, 2011, Pages 317-330

  Ballatore, C ^a,b   Brunden, K R ^b   Trojanowski, J Q ^b   Lee, V M Y ^b   Smith III, A B ^a   Huryn, D M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aggregation inhibitors; Alzheimer's disease; Microtubule stabilizing agents; Neurodegenerative tauopathies; Protein protein interaction; Tau

Indexed keywords

ANG 1005; CERATAMINE A; CERATAMINE B; CNDR 29; CYCLOSTREPTIN; DICTYOSTATIN; DISCODERMOLIDE; DOCETAXEL; ELEUTHEROBIN; EPOTHILONE A; EPOTHILONE B; EPOTHILONE C; EPOTHILONE D; EPOTHILONE DERIVATIVE; IXABEPILONE; LAROTAXEL; LAULIMALIDE; ORTATAXEL; PACLITAXEL; PACLITAXEL DERIVATIVE; PELORUSIDE A; RPR 109881A; SARCODICTYIN A; SARCODICTYIN B; SB T 1213; SB T 121303; TAU PROTEIN; TAXANE DERIVATIVE; TX 67; TXD 258; UNCLASSIFIED DRUG; UNINDEXED DRUG; WS 9885B;

ARTICLE; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; NERVE FIBER TRANSPORT; NONHUMAN; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TAUOPATHY;

ANIMALS; HUMANS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; TAU PROTEINS; TAUOPATHIES; TUBULIN MODULATORS;

EID: 78650929447     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611794072605     Document Type: Article

References (130)

1. Stockwin, L. H.; Holmes, S. Antibodies as therapeutic agents: vivela renaissance. Exp. Opin. Biol. Ther., 2003, 3, 1133-1152.
2. Toogood, P. L. Inhibition of protein-protein association by smallmolecules: approaches and progress. J. Med. Chem., 2002, 45,1543-1558.
3. Fry, D. Protein-protein interactions as targets for small moleculedrug discovery. Biopolymers, 2006, 84, 535-552.
4. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. DrugDiscov., 2004, 3, 301-317.
5. Liu, J.; Albers, M. W.; Wandless, T. J.; Luan, S.; Alberg, D. G.; Belshaw, P. J.; Cohen, P.; MacKintosh, C.; Klee, C. B.; Schreiber,S. L. Inhibition of T cell signaling by immunophilin-ligandcomplexes correlates with loss of calcineurin phosphatase activity.Biochemistry, 1992, 31, 3896-3901.
6. Liu, J.; Farmer, J. D.; Lane, W. S.; Friedman, J.; Weissman, I.; Schreiber, S. L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell, 1991, 66, 807-815.
7. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancerdrugs. Nat. Rev. Cancer, 2004, 4, 253-265.
8. Berg, T. Modulation of protein-protein interactions with smallorganic molecules. Angew. Chem. Int. Ed. Engl., 2003, 42, 2462-2481.
9. Lee, V. M.-Y.; Goedert, M.; Trojanowski, J. Q. Neurodegenerativetauopathies. Ann. Rev. Neurosci., 2001, 24, 1121-1159.
10. Ballatore, C.; Lee, V. M.-Y.; Trojanowski, J. Q. Tau-mediatedneurodegeneration in Alzheimer's disease and related disorders.Nat. Rev. Neurosci., 2007, 8, 663-672.
11. Roy, S.; Zhang, B.; Lee, V. M.-Y.; Trojanowski, J. Q. Axonaltransport defects: a common theme in neurodegenerative diseases.Acta. Neuropathol. (Berl.), 2005, 109, 5-13.
12. Panda, D.; Samuel, J. C.; Massie, M.; Feinstein, S. C.; Wilson, L.Differential regulation of microtubule dynamics by three-and four-repeat tau: implications for the onset of neurodegenerative disease.Proc. Natl. Acad. Sci. USA, 2003, 100, 9548-9553.
13. Bunker, J. M.; Wilson, L.; Jordan, M. A.; Feinstein, S. C.Modulation of microtubule dynamics by tau in living cells:implications for development and neurodegeneration. Mol. Biol.Cell, 2004, 15, 2720-2728.
14. Mackenzie, I.; Neumann, M.; Bigio, E.; Cairns, N.; Alafuzoff, I.; Kril, J.; Kovacs, G.; Ghetti, B.; Halliday, G.; Holm, I.Nomenclature and nosology for neuropathologic subtypes offrontotemporal lobar degeneration: an update. Acta Neuropathol.(Berl.), 2010, 119, 1-4.
15. Hong, M.; Zhukareva, V.; Vogelsberg-Ragaglia, V.; Wszolek, Z.; Reed, L.; Miller, B. I.; Geschwind, D. H.; Bird, T. D.; McKeel, D.; Goate, A.; Morris, J. C.; Wilhelmsen, K. C.; Schellenberg, G. D.; Trojanowski, J. Q.; Lee, V. M. Y. Mutation-specific functionalimpairments in distinct tau isoforms of hereditary FTDP-17.Science, 1998, 282, 1914-1917.
16. Amos, L. A. Microtubule structure and its stabilisation. Org.Biomol. Chem., 2004, 2, 2153-2160.
17. Congdon, E. E.; Kim, S.; Bonchak, J.; Songrug, T.; Matzavinos,A.; Kuret, J. Nucleation-dependent tau filament formation: theimportance of dimerization and an estimation of elementary rateconstants. J. Biol. Chem., 2008, 283, 13806-13816.
18. Drubin, D. G.; Feinstein, S. C.; Shooter, E. M.; Kirschner, M. W.Nerve growth factor-induced neurite outgrowth in PC12 cellsinvolves the coordinate induction of microtubule assembly andassembly-promoting factors. J. Cell Biol., 1985, 101, 1799-1807.
19. Mazanetz, M. P.; Fischer, P. M. Untangling tau hyperphos-phorylation in drug design for neurodegenerative diseases. Nat.Rev. Drug Discov. 2007, 6, 464-479.
20. Ross, C. A.; Poirier, M. A. Protein aggregation andneurodegenerative disease. Nat. Med., 2004, 10 (Suppl), S10-17.
21. Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M.-Y. Evidence thatnon-fibrillar tau causes pathology linked to neurodegeneration andbehavioral impairments. J. Alzheimers Dis., 2008, 14, 393-399.
22. Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M.-Y. Advances intau-focused drug discovery for Alzheimer's disease and relatedtauopathies. Nat. Rev. Drug Discov., 2009, 8, 783-793.
23. Zhang, B.; Maiti, A.; Shively, S.; Lakhani, F.; McDonald-Jones, G.; Bruce, J.; Lee, E. B.; Xie, S. X.; Joyce, S.; Li, C.; Toleikis, P.M.; Lee, V. M.-Y.; Trojanowski, J. Q. Microtubule-binding drugsoffset tau sequestration by stabilizing microtubules and reversingfast axonal transport deficits in a tauopathy model. Proc. Natl.Acad. Sci. USA, 2005, 102, 227-231.
24. Brunden, K. R.; Zhang, B.; Carrol, J.; Yao, Y.; Potuzak, J.; Hogan, A.-M.; Iba, M.; James, M.; Xie, S.; Ballatore, C.; Smith, III, A. B.; Lee, V.M.-Y.; Trojanowski, J.Q. Epothilone D improvesmicrotubule density, axonal integrity, and cognition in a transgenicmouse model of tauopathy. J. Neurosci., 2010, 30(41), 13861-13866.
25. Akira Kurose, W. Y. M. Y. T. S. Effects of paclitaxel on culturedsynovial cells from patients with rheumatoid arthritis. Cytometry,2001, 44, 349-354.
26. Ehrlich, A.; Booher, S.; Becerra, Y.; Borris, D. L.; Figg, W. D.; Turner, M. L.; Blauvelt, A. Micellar paclitaxel improves severepsoriasis in a prospective phase II pilot study. J. Am. Acad.Dermatol., 2004, 50, 533-540.
27. Moscarello, M. A.; Mak, B.; Nguyen, T. A.; Wood, D. D.; Mastronardi, F.; Ludwin, S. K. Paclitaxel (Taxol) attenuatesclinical disease in a spontaneously demyelinating transgenic mouseand induces remyelination. Mult. Scler., 2002, 8, 130-138.
28. Lee, V. M.-Y.; Daughenbaugh, R.; Trojanowski, J. Q. Microtubulestabilizing drugs for the treatment of Alzheimer's disease.Neurobiol. Aging, 1994, 15(Suppl) 2, S87-89.
29. Andrieux, A.; Salin, P.; Schweitzer, A.; Begou, M.; Pachoud, B.; Brun, P.; Gory-Faure, S.; Kujala, P.; Suaud-Chagny, M. F.; Hofle, G.; Job, D. Microtubule stabilizer ameliorates synaptic functionand behavior in a mouse model for schizophrenia. Biol. Psychiatry,2006, 60, 1224-1230.
30. Trojanowski, J. Q.; Smith, A. B.; Huryn, D.; Lee, V. M.-Y.Microtubule-stabilizing drugs for therapy of Alzheimer's diseaseand other neurodegenerative disorders with axonal transportimpairments. Expert Opin. Pharmacother., 2005, 6, 683-686.
31. Eiseman, J. L.; Eddington, N. D.; Leslie, J.; MacAuley, C.; Sentz, D. L.; Zuhowski, M.; Kujawa, J. M.; Young, D.; Egorin, M. J.Plasma pharmacokinetics and tissue distribution of paclitaxel inCD2F1 mice. Cancer Chemother. Pharmacol., 1994, 34, 465-471.
32. Markman, M. Managing taxane toxicities. Support. Care Cancer2003, 11, 144-7.
33. Von Hoff, D. D. The taxoids: same roots, different drugs. Semin.Oncol., 1997, 24, S13-3-S13-10.
34. Marupudi, N. I.; Han, J. E.; Li, K. W.; Renard, V. M.; Tyler, B. M.; Brem, H. Paclitaxel: a review of adverse toxicities and noveldelivery strategies. Expert Opin. Drug Saf., 2007, 6, 609-621.
35. Lee, J.; Swain, S. M. Peripheral neuropathy induced bymicrotubule-stabilizing agents. J. Clin. Oncol., 2006, 24, 1633-1642.
36. Nogales, E.; Wolf, S. G.; Khan, I. A.; Luduena, R. F.; Downing, K.H. Structure of tubulin at 6.5 A and location of the taxol-bindingsite. Nature, 1995, 375, 424-427.
37. Kar, S.; Fan, J.; Smith, M. J.; Goedert, M.; Amos, L. A. Repeatmotifs of tau bind to the insides of microtubules in the absence oftaxol. EMBO J., 2003, 22, 70-77.
38. Amos, L. A.; Lowe, J. How Taxol stabilises microtubule structure.Chem. Biol., 1999, 6, R65-69.
39. Derry, W. B.; Wilson, L.; Jordan, M. A. Substoichiometric bindingof taxol suppresses microtubule dynamics. Biochemistry, 1995, 34,2203-2211.
40. Gallo, J. M.; Li, S.; Guo, P.; Reed, K.; Ma, J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution inmice. Cancer Res., 2003, 63, 5114-5117.
41. Fricker, G.; Miller, D. S. Modulation of drug transporters at theblood-brain barrier. Pharmacology, 2004, 70, 169-176.
42. Kemper, E. M.; van Zandbergen, A. E.; Cleypool, C.; Mos, H. A.; Boogerd, W.; Beijnen, J. H.; van Tellingen, O. Increasedpenetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin. Cancer Res., 2003, 9, 2849-2855.
43. Fellner, S.; Bauer, B.; Miller, D. S.; Schaffrik, M.; Fankhanel, M.; Spruss, T.; Bernhardt, G.; Graeff, C.; Farber, L.; Gschaidmeier, H.; Buschauer, A.; Fricker, G. Transport of paclitaxel (Taxol) acrossthe blood-brain barrier in vitro and in vivo. J. Clin. Invest., 2002,110, 1309-1318.
44. van Asperen, J.; van Tellingen, O.; Sparreboom, A.; Schinkel, A.H.; Borst, P.; Nooijen, W. J.; Beijnen, J. H. Enhanced oralbioavailability of paclitaxel in mice treated with the P-glycoproteinblocker SDZ PSC 833. Br. J. Cancer, 1997, 76, 1181-1183.
45. Beaulieu, E.; Demeule, M.; Ghitescu, L.; Beliveau, R. P-glycoprotein is strongly expressed in the luminal membranes of theendothelium of blood vessels in the brain. Biochem. J., 1997, 326(Pt 2), 539-544.
46. Ojima, I.; Chen, J.; Sun, L.; Borella, C. P.; Wang, T.; Miller, M. L.; Lin, S.; Geng, X.; Kuznetsova, L.; Qu, C.; Gallager, D.; Zhao, X.; Zanardi, I.; Xia, S.; Horwitz, S. B.; Mallen-St Clair, J.; Guerriero, J. L.; Bar-Sagi, D.; Veith, J. M.; Pera, P.; Bernacki, R. J. Design,synthesis, and biological evaluation of new-generation taxoids. J.Med. Chem., 2008, 51, 3203-3221.
47. Ojima, I.; Slater, J. C.; Kuduk, S. D.; Takeuchi, C. S.; Gimi, R. H.; Sun, C. M.; Park, Y. H.; Pera, P.; Veith, J. M.; Bernacki, R. J.Syntheses and structure-activity relationships of taxoids derivedfrom 14 beta-hydroxy-10-deacetylbaccatin III. J. Med. Chem.,1997, 40, 267-278.
48. Ojima, I.; Slater, J. C.; Michaud, E.; Kuduk, S. D.; Bounaud, P. Y.; Vrignaud, P.; Bissery, M. C.; Veith, J. M.; Pera, P.; Bernacki, R. J.Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J. Med. Chem., 1996, 39, 3889-3896.
49. Ferlini, C.; Distefano, M.; Pignatelli, F.; Lin, S.; Riva, A.; Bombardelli, E.; Mancuso, S.; Ojima, I.; Scambia, G. Antitumouractivity of novel taxanes that act at the same time as cytotoxicagents and P-glycoprotein inhibitors. Br. J. Cancer, 2000, 83,1762-1768.
50. Vredenburg, M. R.; Ojima, I.; Veith, J.; Pera, P.; Kee, K.; Cabral, F.; Sharma, A.; Kanter, P.; Greco, W. R.; Bernacki, R. J. Effects oforally active taxanes on P-glycoprotein modulation and colon andbreast carcinoma drug resistance. J. Natl. Cancer Inst., 2001, 93,1234-1245.
51. Laccabue, D.; Tortoreto, M.; Veneroni, S.; Perego, P.; Scanziani, E.; Zucchetti, M.; Zaffaroni, M.; D'Incalci, M.; Bombardelli, E.; Zunino, F.; Pratesi, G. A novel taxane active against anorthotopically growing human glioma xenograft. Cancer, 2001, 92,3085-3092.
52. Minderman, H.; Brooks, T. A.; O'Loughlin, K. L.; Ojima, I.; Bernacki, R. J.; Baer, M. R. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivativesortataxel (IDN-5109, BAY 59-8862) and tRA96023. CancerChemother. Pharmacol., 2004, 53, 363-369.
53. Cisternino, S.; Bourasset, F.; Archimbaud, Y.; Semiond, D.; Sanderink, G.; Scherrmann, J. M. Nonlinear accumulation in thebrain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br. J.Pharmacol., 2003, 138, 1367-1375.
54. Metzger-Filho, O.; Moulin, C.; de Azambuja, E.; Ahmad, A.Larotaxel: broadening the road with new taxanes. Expert. Opin.Investig. Drugs, 2009, 18, 1183-1189.
55. Sessa, C.; Cuvier, C.; Caldiera, S.; Bauer, J.; Van den Bosch, S.; Monnerat, C.; Semiond, D.; Perard, D.; Lebecq, A.; Besenval, M.; Marty, M. Phase I clinical and pharmacokinetic studies of thetaxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann. Oncol.,2002, 13, 1140-1150.
56. Cirrito, J. R.; Deane, R.; Fagan, A. M.; Spinner, M. L.; Parsadanian, M.; Finn, M. B.; Jiang, H.; Prior, J. L.; Sagare, A.; Bales, K. R.; Paul, S. M.; Zlokovic, B. V.; Piwnica-Worms, D.; Holtzman, D. M. P-glycoprotein deficiency at the blood-brainbarrier increases amyloid-{beta} deposition in an Alzheimerdisease mouse model. J. Clin. Invest., 2005, 115, 3285-3290.
57. Rice, A.; Liu, Y.; Michaelis, M. L.; Himes, R. H.; Georg, G. I.; Audus, K. L. Chemical modification of paclitaxel (Taxol) reducesP-glycoprotein interactions and increases permeation across theblood-brain barrier in vitro and in situ. J. Med. Chem., 2005, 48,832-838.
58. Ballatore, C.; Hyde, E.; Deiches, R. F.; Lee, V. M.-Y.; Trojanowski, J. Q.; Huryn, D.; Smith, A. B., III. Paclitaxel C-10carbamates: potential candidates for the treatment ofneurodegenerative tauopathies. Bioorg. Med. Chem. Lett., 2007, 17,3642-3646.
59. Ballatore, C.; Zhang, B.; Trojanowski, J. Q.; Lee, V. M.; Smith, A.B., 3rd. In situ blood-brain barrier permeability of a C-10 paclitaxelcarbamate. Bioorg. Med. Chem. Lett., 2008, 18, 6119-6121.
60. Regina, A.; Demeule, M.; Che, C.; Lavallee, I.; Poirier, J.; Gabathuler, R.; Beliveau, R.; Castaigne, J. P. Antitumour activityof ANG1005, a conjugate between paclitaxel and the new braindelivery vector Angiopep-2. Br. J. Pharmacol., 2008, 155, 185-197.
61. Demeule, M.; Regina, A.; Che, C.; Poirier, J.; Nguyen, T.; Gabathuler, R.; Castaigne, J. P.; Beliveau, R. Identification anddesign of peptides as a new drug delivery system for the brain. J.Pharmacol. Exp. Ther., 2008, 324, 1064-1072.
62. Hofle, G.; Reichenbach, H. Anticancer agents from naturalproducts. In Anticancer agents from natural products, CRC PressLLC: Boca Raton, FL, 2005, pp 413-450.
63. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, anew class of microtubule-stabilizing agents with a taxol-likemechanism of action. Cancer Res., 1995, 55, 2325-2333.
64. Kowalski, R. J.; Giannakakou, P.; Hamel, E. Activities of themicrotubule-stabilizing agents epothilones A and B with purifiedtubulin and in cells resistant to paclitaxel (Taxol(R)). J. Biol.Chem., 1997, 272, 2534-2541.
65. Giannakakou, P.; Gussio, R.; Nogales, E.; Downing, K. H.; Zaharevitz, D.; Bollbuck, B.; Poy, G.; Sackett, D.; Nicolaou, K. C.; Fojo, T. A common pharmacophore for epothilone and taxanes:molecular basis for drug resistance conferred by tubulin mutationsin human cancer cells. Proc. Natl. Acad. Sci. USA, 2000, 97, 2904-2909.
66. He, L.; Yang, C. P.; Horwitz, S. B. Mutations in beta-tubulin mapto domains involved in regulation of microtubule stability inepothilone-resistant cell lines. Mol. Cancer Ther., 2001, 1, 3-10.
67. Nicolaou, K. C. R., F; Vourloumis, D. Chemical biology ofepothilones. Angew. Chem. Int. Ed. Engl., 1998, 37, 2014-2045.
68. Altmann, K. H. Epothilone B and its analogs - a new family ofanticancer agents. Mini Rev. Med. Chem., 2003, 3, 149-158.
69. Altmann, K. H.; Pfeiffer, B.; Arseniyadis, S.; Pratt, B. A.; Nicolaou, K. C. The chemistry and biology of epothilones-thewheel keeps turning. Chem. Med. Chem., 2007, 2, 396-424.
70. Conlin, A.; Fornier, M.; Hudis, C.; Kar, S.; Kirkpatrick, P.Ixabepilone. Nat. Rev. Drug. Discov., 2007, 6, 953-954.
71. Michaelis, M. L.; Ansar, S.; Chen, Y.; Reiff, E. R.; Seyb, K. I.; Himes, R. H.; Audus, K. L.; Georg, G. I. {beta}-Amyloid-inducedneurodegeneration and protection by structurally diversemicrotubule-stabilizing agents. J. Pharmacol. Exp. Ther., 2005,312, 659-668.
72. Harris, C. R.; Danishefsky, S. J. Complex target-oriented synthesisin the drug discovery process: A case history in the dEpoB series.J. Org. Chem., 1999, 64, 8434-8456.
73. Lichtner, R. M. R., A.; Klar, U.; Hoffmann, J.; Buchmann, B.; Schwede, W.; Skuballa, W. The use of epothilones in the treatmentof brain diseases associated with proliferative process. WO03/074053 A1, 2003.
74. O'Reilly, T.; Wartmann, M.; Brueggen, J.; Allegrini, P. R.; Floersheimer, A.; Maira, M.; McSheehy, P. M. Pharmacokineticprofile of the microtubule stabilizer patupilone in tumor-bearingrodents and comparison of anti-cancer activity with other MTS invitro and in vivo. Cancer Chemother Pharmacol., 2008, 62, 1045-1054.
75. Laferriere, N.; MacRae, T.; Brown, D. Tubulin synthesis andassembly in differentiating neurons. Biochem. Cell Biol., 1997, 75,103-117.
76. Black, M.; Baas, P.; Humphries, S. Dynamics of alpha-tubulindeacetylation in intact neurons. J. Neurosci., 1989, 9, 358-368.
77. Albright, C. F.; Barten, D. M.; Lee, F. Y. Use of epothilone D intreating tau-associated diseases including Alzheimer's disease.US2009/0270465A1, 2009.
78. Santacruz, K.; Lewis, J.; Spires, T.; Paulson, J.; Kotilinek, L.; Ingelsson, M.; Guimaraes, A.; DeTure, M.; Ramsden, M.; McGowan, E.; Forster, C.; Yue, M.; Orne, J.; Janus, C.; Mariash,A.; Kuskowski M.; Hyman, B.; Hutton, M.; Ashe, K. H. Tausuppression in a neurodegenerative mouse model improvesmemory function. Science, 2005, 309, 476-481.
79. Kowalski, R. J.; Giannakakou, P.; Gunasekera, S. P.; Longley, R.E.; Day, B. W.; Hamel, E. The microtubule-stabilizing agentdiscodermolide competitively inhibits the binding of paclitaxel(Taxol) to tubulin polymers, enhances tubulin nucleation reactionsmore potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol. Pharmacol., 1997, 52, 613-622.
80. Hamel, E.; Sackett, D. L.; Vourloumis, D.; Nicolaou, K. C. Thecoral-derived natural products eleutherobin and sarcodictyins Aand B: effects on the assembly of purified tubulin with and withoutmicrotubule-associated proteins and binding at the polymer taxoidsite. Biochemistry, 1999, 38, 5490-5498.
81. Madiraju, C.; Edler, M. C.; Hamel, E.; Raccor, B. S.; Balachandran, R.; Zhu, G.; Giuliano, K. A.; Vogt, A.; Shin, Y.; Fournier, J. H.; Fukui, Y.; Bruckner, A. M.; Curran, D. P.; Day, B.W. Tubulin assembly, taxoid site binding, and cellular effects ofthe microtubule-stabilizing agent dictyostatin. Biochemistry, 2005,44, 15053-15063.
82. Ojima, I.; Chakravarty, S.; Inoue, T.; Lin, S.; He, L.; Horwitz, S.B.; Kuduk, S. D.; Danishefsky, S. J. A common pharmacophore forcytotoxic natural products that stabilize microtubules. Proc. Natl.Acad. Sci. USA, 1999, 96, 4256-4261.
83. Honore, S.; Kamath, K.; Braguer, D.; Horwitz, S. B.; Wilson, L.; Briand, C.; Jordan, M. A. Synergistic suppression of microtubuledynamics by discodermolide and paclitaxel in non-small cell lungcarcinoma cells. Cancer Res., 2004, 64, 4957-4964.
84. Martello, L. A.; McDaid, H. M.; Regl, D. L.; Yang, C. P.; Meng, D.; Pettus, T. R.; Kaufman, M. D.; Arimoto, H.; Danishefsky, S. J.; Smith, A. B., III; Horwitz, S. B. Taxol and discodermoliderepresent a synergistic drug combination in human carcinoma celllines. Clin. Cancer Res., 2000, 6, 1978-1987.
85. Huang, G. S.; Lopez-Barcons, L.; Freeze, B. S.; Smith, A. B., III; Goldberg, G. L.; Horwitz, S. B.; McDaid, H. M. Potentiation oftaxol efficacy by discodermolide in ovarian carcinoma xenograft-bearing mice. Clin. Cancer Res., 2006, 12, 298-304.
86. Long, B. H.; Carboni, J. M.; Wasserman, A. J.; Cornell, L. A.; Casazza, A. M.; Jensen, P. R.; Lindel, T.; Fenical, W.; Fairchild, C.R. Eleutherobin, a novel cytotoxic agent that induces tubulinpolymerization, is similar to paclitaxel (Taxol (R)). Cancer Res.,1998, 58, 1111-1115.
87. Isbrucker, R. A.; Cummins, J.; Pomponi, S. A.; Longley, R. E.; Wright, A. E. Tubulin polymerizing activity of dictyostatin-1, apolyketide of marine sponge origin. Biochem. Pharmacol., 2003,66, 75-82.
88. Edler, M. C.; Buey, R. M.; Gussio, R.; Marcus, A. I.; Vanderwal, C. D.; Sorensen, E. J.; Diaz, J. F.; Giannakakou, P.; Hamel, E.Cyclostreptin (FR182877), an antitumor tubulin-polymerizingagent deficient in enhancing tubulin assembly despite its highaffinity for the taxoid site. Biochemistry, 2005, 44, 11525-11538.
89. Buey, R. M.; Calvo, E.; Barasoain, I.; Pineda, O.; Edler, M. C.; Matesanz, R.; Cerezo, G.; Vanderwal, C. D.; Day, B. W.; Sorensen, E. J.; Lopez, J. A.; Andreu, J. M.; Hamel, E.; Diaz, J. F.Cyclostreptin binds covalently to microtubule pores and lumenaltaxoid binding sites. Nat. Chem. Biol., 2007, 3, 117-125.
90. Bai, R.; Vanderwal, C. D.; Diaz, J. F.; Hamel, E. Interaction of acyclostreptin analogue with the microtubule taxoid site: thecovalent reaction rapidly follows binding. J. Nat. Prod., 2008, 71,370-374.
91. Martello, L. A.; LaMarche, M. J.; He, L.; Beauchamp, T. J.; Smith, A. B., III; Horwitz, S. B. The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies. Chem.Biol., 2001, 8, 843-855.
92. Gertsch, J.; Meier, S.; Müller, M.; Altmann, K.-H. Differentialeffects of natural product microtubule stabilizers on microtubuleassembly: single agent and combination studies with taxol,epothilone B, and discodermolide. ChemBioChem, 2009, 10, 166-175.
93. Gaitanos, T. N.; Buey, R. M.; Diaz, J. F.; Northcote, P. T.; Teesdale-Spittle, P.; Andreu, J. M.; Miller, J. H. Peloruside A doesnot bind to the taxoid site on beta-tubulin and retains its activity inmultidrug-resistant cell lines. Cancer Res., 2004, 64, 5063-5067.
94. Huzil, J. T.; Chik, J. K.; Slysz, G. W.; Freedman, H.; Tuszynski, J.; Taylor, R. E.; Sackett, D. L.; Schriemer, D. C. A Unique mode ofmicrotubule stabilization induced by peloruside A. J. Mol. Biol.,2008, 378, 1016-1030.
95. Mooberry, S. L.; Tien, G.; Hernandez, A. H.; Plubrukarn, A.; Davidson, B. S. Laulimalide and isolaulimalide, new paclitaxel-likemicrotubule-stabilizing agents. Cancer Res., 1999, 59, 653-660.
96. Pryor, D. E.; O'Brate, A.; Bilcer, G.; Diaz, J. F.; Wang, Y.; Kabaki, M.; Jung, M. K.; Andreu, J. M.; Ghosh, A. K. The microtubulestabilizing agent laulimalide does not bind in the taxoid site, killscells resistant to paclitaxel and epothilones, and may not require itsepoxide moiety for activity. Biochemistry, 2002, 41, 9109-9115.
97. Karjala, G.; Chan, Q.; Manzo, E.; Andersen, R. J.; Roberge, M.Ceratamines, structurally simple microtubule-stabilizing antimitoticagents with unusual cellular effects. Cancer Res., 2005, 65, 3040-3043.
98. Hamel, E.; Day, B. W.; Miller, J. H.; Jung, M. K.; Northcote, P. T.; Ghosh, A. K.; Curran, D. P.; Cushman, M.; Nicolaou, K. C.; Paterson, I. Synergistic effects of peloruside A and laulimalide withtaxoid site drugs, but not with each other, on tubulin assembly.Mol. Pharmacol., 2006, 70, 1555-1564.
99. Tinley, T. L.; Randall-Hlubek, D. A.; Leal, R. M.; Jackson, E. M.; Cessac, J. W.; Quada, J. C., Jr.; Hemscheidt, T. K.; Mooberry, S. L.Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res., 2003, 63, 3211-3220.
100. Buey, R. M.; Barasoain, I.; Jackson, E.; Meyer, A.; Giannakakou, P.; Paterson, I.; Mooberry, S.; Andreu, J. M.; DÌaz, J. F.Microtubule interactions with chemically diverse stabilizing agents:thermodynamics of binding to the paclitaxel site predictscytotoxicity. Chem. Biol., 2005, 12, 1269-1279.
101. Divinski, I.; Mittelman, L.; Gozes, I. A femtomolar actingoctapeptide interacts with tubulin and protects astrocytes againstzinc intoxication. J. Biol. Chem., 2004, 279, 28531-28538.
102. Gozes, I.; Morimoto, B. H.; Tiong, J.; Fox, A.; Sutherland, K.; Dangoor, D.; Holser-Cochav, M.; Vered, K.; Newton, P.; Aisen, P.S. NAP: research and development of a peptide derived fromactivity-dependent neuroprotective protein (ADNP). CNS DrugRev., 2005, 11, 353-378.
103. Vulih-Shultzman, I.; Pinhasov, A.; Mandel, S.; Grigoriadis, N.; Touloumi, O.; Pittel, Z.; Gozes, I. Activity-dependentneuroprotective protein snippet NAP reduces tau hyperphos-phorylation and enhances learning in a novel transgenic mousemodel. J. Pharmacol. Exp. Ther., 2007, 323, 438-449.
104. Morimoto, B. H.; LannOy, I.; Fox, A. W.; Gozes, I.; Stewart, A.pharmacokinetics and distribution to brain after intravenous orintranasal administration to rat. Chim. Oggi., 2009, 27, 16-20.
105. Xu, S.; Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M. Y.Characterization of tau fibrillization in vitro. Alzheimer's Dement.,2010, 6(2), 110-117.
106. Goedert, M.; Jakes, R.; Spillantini, M. G.; Hasegawa, M.; Smith, M. J.; Crowther, R. A. Assembly of microtubule-associated proteintau into Alzheimer-like filaments induced by sulphatedglycosaminoglycans. Nature, 1996, 383, 550-553.
107. Chirita, C. N.; Necula, M.; Kuret, J. Anionic micelles and vesiclesinduce tau fibrillization in vitro. J. Biol. Chem., 2003, 278, 25644-25650.
108. Crowe, A.; Ballatore, C.; Hyde, E.; Trojanowski, J. Q.; Lee, V. M.-Y. High throughput screening for small molecule inhibitors ofheparin-induced tau fibril formation. Biochem. Biophy. Res.Commun., 2007, 358, 1-6.
109. Pickhardt, M.; Gazova, Z.; von Bergen, M.; Khlistunova, I.; Wang, Y.; Hascher, A.; Mandelkow, E. M.; Biernat, J.; Mandelkow, E.Anthraquinones inhibit tau aggregation and dissolve Alzheimer'spaired helical filaments in vitro and in cells. J. Biol. Chem., 2005,280, 3628-3635.
110. Crowe, A.; Huang, W.; Ballatore, C.; Johnson, R. L.; Hogan, A.M.; Huang, R.; Wichterman, J.; McCoy, J.; Huryn, D.; Auld, D. S.; Smith, A. B., III; Inglese, J.; Trojanowski, J. Q.; Austin, C. P.; Brunden, K. R.; Lee, V. M.-Y. Identification of aminothieno-pyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry, 2009, 48, 7732-7745.
111. Groenning, M. Binding mode of Thioflavin T and other molecularprobes in the context of amyloid fibrils-current status. J. Chem.Biol. 2009.
112. Bulic, B.; Pickhardt, M.; Schmidt, B.; Mandelkow, E. M.; Waldmann, H.; Mandelkow, E. Development of tau aggregationinhibitors for Alzheimer's disease. Angew. Chem. Int. Ed. Engl.,2009, 48, 2-15.
113. Brunden, K. R.; Ballatore, C.; Crowe, A.; Smith, A. B., III; Lee, V.M.-Y.; Trojanowski, J. Q. Tau-directed drug discovery forAlzheimer's disease and related tauopathies: A focus on tauassembly inhibitors. Exp. Neurol., 2009, 223, 304-310.
114. Taniguchi, S.; Suzuki, N.; Masuda, M.; Hisanaga, S.; Iwatsubo, T.; Goedert, M.; Hasegawa, M. Inhibition of heparin-induced taufilament formation by phenothiazines, polyphenols, andporphyrins. J. Biol. Chem., 2005, 280, 7614-7623.
115. Chirita, C.; Necula, M.; Kuret, J. Ligand-dependent inhibition andreversal of tau filament formation. Biochemistry, 2004, 43, 2879-2887.
116. Khlistunova, I.; Biernat, J.; Wang, Y.; Pickhardt, M.; von Bergen, M.; Gazova, Z.; Mandelkow, E.; Mandelkow, E.-M. InducibleExpression of Tau Repeat Domain in Cell Models of Tauopathy:Aggregation is toxic to cells but can be reversed by inhibitor drugs.J. Biol. Chem., 2006, 281, 1205-1214.
117. Pickhardt, M.; Larbig, G.; Khlistunova, I.; Coksezen, A.; Meyer, B.; Mandelkow, E. M.; Schmidt, B.; Mandelkow, E.Phenylthiazolyl-hydrazide and its derivatives are potent inhibitorsof tau aggregation and toxicity in vitro and in cells. Biochemistry,2007, 46, 10016-10023.
118. Bulic, B.; Pickhardt, M.; Khlistunova, I.; Biernat, J.; Mandelkow, E. M.; Mandelkow, E.; Waldmann, H. Rhodanine-based tauaggregation inhibitors in cell models of tauopathy. Angew. Chem.Int. Ed. Engl., 2007, 46, 9215-9219.
119. Smith, A. B., III; Sperry, J. B.; Han, Q. Syntheses of (-)-oleocanthal, a natural NSAID found in extra virgin olive oil, the(-)-deacetoxy-oleuropein aglycone, and related analogues. J. Org.Chem., 2007, 72, 6891-6900.
120. Smith III, A. B.; Han, Q.; Breslin, P. A. S.; Beauchamp, G. K.Synthesis and assignment of absolute configuration of (-)-oleocanthal: a potent, naturally occurring non-steroidal anti-inflammatory and anti-oxidant agent derived from extra virginolive oils. Org. Lett., 2005, 7, 5075-5078.
121. Li, W.; Sperry, J. B.; Crowe, A.; Trojanowski, J. Q.; Smith, A. B. III; Lee, V. M. Y. Inhibition of tau fibrillization by oleocanthal viareaction with the amino groups of tau. J. Neurochem., 2009, 110,1339-1351.
122. Pickhardt, M.; Biernat, J.; Khlistunova, I.; Wang, Y. P.; Gazova, Z.; Mandelkow, E. M.; Mandelkow, E. N-phenylamine derivativesas aggregation inhibitors in cell models of tauopathy. Curr.Alzheimer Res., 2007, 4, 397-402.
123. Necula, M.; Chirita, C. N.; Kuret, J. Cyanine dye N744 inhibits taufibrillization by blocking filament extension: implications for thetreatment of tauopathic neurodegenerative diseases. Biochemistry,2005, 44, 10227-10237.
124. Congdon, E. E.; Necula, M.; Blackstone, R. D.; Kuret, J. Potencyof a tau fibrillization inhibitor is influenced by its aggregation state.Arch. Bichem. Biophys., 2007, 465, 127-135.
125. Chang, E.; Congdon, E. E.; Honson, N. S.; Duff, K. E.; Kuret, J.Structure-activity relationship of cyanine tau aggregationinhibitors. J. Med. Chem., 2009, 52, 3539-3547.
126. Congdon, E. E.; Figueroa, Y. H.; Wang, L.; Tonuva, G.; Chang, E.; Kuret, J.; Conrad, C.; Duff, K. E. Inhibition of tau polymerizationwith a cyanine dye in two distinct model systems. J. Biol. Chem.,2009,284, 20830-20839.
127. Wainwright, M.; Crossley, K. B. Methylene Blue - a therapeuticdye for all seasons? J. Chemother., 2002, 14, 431-443.
128. Peter, C.; Hongwan, D.; Küpfer, A.; Lauterburg, B. H.Pharmacokinetics and organ distribution of intravenous and oralmethylene blue. Eur. J. Clin. Pharmacol., 2000, 56, 247-250.
129. Wischik, C. M.; Edwards, P. C.; Lai, R. Y. K.; Roth, M.; Harrington, C. R. Selective inhibition of Alzheimer disease-like tauaggregation by phenothiazines. Proc. Natl. Acad. Sci. U S A, 1996,93, 11213-11218.
130. Ballatore, C.; Brunden, K. R.; Piscitelli, F.; James, M.; Crowe, A.; Yao, M.; Hyde, E.; Trojanowski, J. Q.; Lee, V. M.-Y.; Smith, A.B., III. J. Med. Chem., 2010, 53, 3739-3747.